Relative Bioavailability of Two Fixed Dose Combination Tablets of Linagliptin/Pioglitazone Compared With Single Linagliptin and Pioglitazone Tablets Administered Together to Healthy Male and Female Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

December 31, 2009

Conditions

Healthy

Interventions

DRUG

Linagliptin/pioglitazone, FDC formulation C5

film coated tablet (5 mg/45 mg)

DRUG

Linagliptin/pioglitazone, FDC formulation C8

film coated tablet (5 mg/45 mg)

DRUG

Linagliptin tablet

5 mg

DRUG

pioglitazone tablet (Actos®)

45 mg